Final overall survival (OS) analysis of PROfound: Olaparib vs physician's choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations
No Thumbnail Available
Identifiers
Date
2020-09-01
Authors
de Bono, J. S.
Mateo, J.
Fizazi, K.
Saad, F.
Shore, N.
Sandhu, S.
Chi, K. N.
Sartor, O.
Agarwal, N.
Olmos, D.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Metrics
Export
